C L Tso
Overview
Explore the profile of C L Tso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
289
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tso C, Zisman A, Pantuck A, Calilliw R, Hernandez J, Paik S, et al.
Cancer Res
. 2001 Nov;
61(21):7925-33.
PMID: 11691814
Immunotherapy targeting for the induction of a T-cell-mediated antitumor response in patients with renal cell carcinoma (RCC) appears to hold significant promise. Here we describe a novel RCC vaccine strategy...
2.
Belldegrun A, Tso C, Zisman A, Naitoh J, Said J, Pantuck A, et al.
Hum Gene Ther
. 2001 Jun;
12(8):883-92.
PMID: 11387054
Twenty-four patients with locally advanced prostate cancer (CaP) were enrolled in a phase I clinical trial using gene-based immunotherapy. A functional DNA-lipid complex encoding the interleukin 2 (IL-2) gene (Leuvectin;...
3.
Tso C, McBride W, Sun J, Patel B, Tsui K, Paik S, et al.
Cancer J
. 2000 Oct;
6(4):220-33.
PMID: 11038142
Purpose: The mechanism of progression of human prostate cancer (CaP) cells under androgen ablation therapy remains unclear. To study the alternative pathways of CaP cell growth under conditions of androgen...
4.
Patel B, Pantuck A, Zisman A, Tsui K, Paik S, Caliliw R, et al.
J Urol
. 2000 Sep;
164(4):1420-5.
PMID: 10992426
Purpose: The mechanisms responsible for tumor progression to androgen independence in prostate cancer (CaP) remain unknown. To characterize these changes and provide a basis for rational therapeutic strategies for advanced...
5.
Hinkel A, Tso C, Gitlitz B, Neagos N, Schmid I, Paik S, et al.
J Immunother
. 2000 Feb;
23(1):83-93.
PMID: 10687141
Dendritic cells (DCs) loaded with tumor antigens have the potential to become a powerful tool for clinical cancer treatment. Recently, the authors showed that a tumor-specific immune response can be...
6.
Mulders P, Tso C, Gitlitz B, Kaboo R, Hinkel A, Frand S, et al.
Clin Cancer Res
. 1999 Feb;
5(2):445-54.
PMID: 10037196
The clinical impact of dendritic cells (DCs) in the treatment of human cancer depends on their unique role as the most potent antigen-presenting cells that are capable of priming an...
7.
Mulders P, Tso C, Pang S, Kaboo R, McBride W, Hinkel A, et al.
J Immunother
. 1998 Jun;
21(3):170-80.
PMID: 9610908
Combination therapy with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes (TILs) demonstrates significant clinical activity in patients with metastatic renal cell carcinoma (RCC). To investigate whether local delivery of IL-2 via gene...
8.
Mulders P, Pang S, Dannull J, Kaboo R, Hinkel A, Michel K, et al.
Cancer Res
. 1998 Mar;
58(5):956-61.
PMID: 9500456
Dendritic cells (DCs) are capable of presenting tumor-associated antigens and subsequently play an essential role in T-cell activation. The aim of this study was to develop an efficient method for...
9.
Syljuasen R, Belldegrun A, Tso C, Withers H, McBride W
Radiat Res
. 1997 Nov;
148(5):443-8.
PMID: 9355869
The rationale for this study was that local delivery of interferon-alpha (IFN-alpha) by gene transfection may be of value during radiotherapy. To investigate the feasibility of this approach, cells of...
10.
Figlin R, PIERCE W, Kaboo R, Tso C, Moldawer N, Gitlitz B, et al.
J Urol
. 1997 Sep;
158(3 Pt 1):740-5.
PMID: 9258071
Purpose: Metastatic renal cell carcinoma is a disease with a mean survival of 6 to 10 months. Interleukin-2 (IL-2), the only approved therapy for metastatic renal cell carcinoma, is associated...